Log In
Print this Print this

orBec, beclomethasone dipropionate

  Manage Alerts
Collapse Summary General Information
Company Soligenix Inc.
DescriptionOral locally-acting therapy consisting of 2 tablets, 1 intended to release beclomethasone dipropionate (BDP) in the proximal portions of the GI tract and the other to release BDP in the distal portions
Molecular Target Glucocorticoid receptor (GCCR)
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today